Toll Free: 1-888-928-9744
Published: Apr, 2017 | Pages:
56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Contact Dermatitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H1 2017, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape. Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 7 respectively. Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology). - The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Contact Dermatitis - Overview Contact Dermatitis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Contact Dermatitis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Contact Dermatitis - Companies Involved in Therapeutics Development Anacor Pharmaceuticals Inc AskAt Inc Brickell Biotech Inc Dr. August Wolff GmbH & Co KG Arzneimittle Edesa Biotech Inc Hapten Sciences Inc ILiAD Biotechnologies LLC Marinomed Biotechnologie GmbH Novartis AG Signum Dermalogix Inc Contact Dermatitis - Drug Profiles AAT-008 - Drug Profile Product Description Mechanism Of Action R&D Progress AN-3485 - Drug Profile Product Description Mechanism Of Action R&D Progress BBI-2000 - Drug Profile Product Description Mechanism Of Action R&D Progress beta-escin - Drug Profile Product Description Mechanism Of Action R&D Progress EB-01 - Drug Profile Product Description Mechanism Of Action R&D Progress EB-05 - Drug Profile Product Description Mechanism Of Action R&D Progress grapiprant - Drug Profile Product Description Mechanism Of Action R&D Progress HPT-721 - Drug Profile Product Description Mechanism Of Action R&D Progress pertussis [strain BPZE1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress secukinumab - Drug Profile Product Description Mechanism Of Action R&D Progress SIG-1322 - Drug Profile Product Description Mechanism Of Action R&D Progress WOL-071007 - Drug Profile Product Description Mechanism Of Action R&D Progress Contact Dermatitis - Dormant Projects Contact Dermatitis - Discontinued Products Contact Dermatitis - Product Development Milestones Featured News & Press Releases Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Contact Dermatitis, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Contact Dermatitis - Pipeline by Anacor Pharmaceuticals Inc, H1 2017 Contact Dermatitis - Pipeline by AskAt Inc, H1 2017 Contact Dermatitis - Pipeline by Brickell Biotech Inc, H1 2017 Contact Dermatitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017 Contact Dermatitis - Pipeline by Edesa Biotech Inc, H1 2017 Contact Dermatitis - Pipeline by Hapten Sciences Inc, H1 2017 Contact Dermatitis - Pipeline by ILiAD Biotechnologies LLC, H1 2017 Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2017 Contact Dermatitis - Pipeline by Novartis AG, H1 2017 Contact Dermatitis - Pipeline by Signum Dermalogix Inc, H1 2017 Contact Dermatitis - Dormant Projects, H1 2017 Contact Dermatitis - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.